Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.59 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548338 | 0.89 | POLB (0.58) | POLBSPHK2SPHK1LMNASMN1; SMN2 | |
| SCHEMBL4212055 | 0.89 | POLB (0.77) | POLBLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1548658 | 0.84 | POLB (0.53) | POLBSPHK2SPHK1 | |
| SCHEMBL2734556 | 0.83 | SPHK2 (0.55) | POLBSPHK2SPHK1ALDH1A1LMNA | |
| SCHEMBL133608 | 0.83 | SPHK2 (0.58) | POLBSPHK2SPHK1ALDH1A1LMNA | |
| SCHEMBL1548365 | 0.81 | SPHK2 (0.57) | POLBSPHK2SPHK1ALDH1A1LMNA | |
| SCHEMBL132328 | 0.81 | SPHK2 (0.59) | POLBSPHK2SPHK1ALDH1A1LMNA | |
| SCHEMBL1548963 | 0.81 | SPHK2 (0.60) | POLBSPHK2SPHK1LMNASMN1; SMN2 | |
| SCHEMBL1548100 | 0.81 | SPHK2 (0.69) | POLBSPHK2SPHK1LMNASMN1; SMN2 | |
| SCHEMBL1548985 | 0.81 | SPHK2 (0.52) | POLBSPHK2SPHK1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-21 | — | — | US | claimed |
| US-20250325577-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD (IL) | 2025-10-23 | — | — | US | disclosed |
| US-12370206-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2025-07-29 | — | — | US | disclosed |
| US-20240108643-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD (IL) | 2024-04-04 | — | — | US | disclosed |
| US-RE49811-E1 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2024-01-23 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-11633385-B2 | Combination compositions for treatment of cancer | REDHILL BIOPHARMA LTD. (IL) | 2023-04-25 | — | — | US | disclosed |
| EP-4134076-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | Redhill Biopharma Ltd. (IL) | 2023-02-15 | — | — | EP | disclosed |
| US-20220160692-A1 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (FR) | 2022-05-26 | — | — | US | disclosed |
| EP-3952850-A1 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-02-16 | — | — | EP | disclosed |
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD. (IL) | 2016-04-28 | — | — | US | disclosed |
| EP-1904439-B1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTHECHNOLOGY CORP (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-8063248-B2 | 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acidisopropylamide; antiproliferative, antiinflammatory agent, angiogenesis inhibitor; sphingolipid-derived signaling pathway; coupling acid or acylhalide of phenyl-adamantane derivatives with aminoalkyl-pyridine | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2314574-A1 | Sphingosine kinase inhibitors | Apogee Biothechnology Corporation (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | RNMT, EIF2AK2, POLRMT | POLB 68/4885SPHK2 975/4885SPHK1 922/4885 |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, S1PR1 | POLB 2648/4885SPHK2 2/4885SPHK1 1/4885 |
| US-20240108643-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | EIF2AK2, RNMT, FBL | POLB 71/4885SPHK2 1080/4885SPHK1 1082/4885 |
| US-20220160692-A1 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | SPHK2, SPHK1, S1PR2 | POLB 2358/4885SPHK2 1/4885SPHK1 2/4885 |
| US-20250325577-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | EIF2AK2, RNMT, FBL | POLB 71/4885SPHK2 1080/4885SPHK1 1082/4885 |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | SPHK2, SPHK1, S1PR2 | POLB 1100/4885SPHK2 1/4885SPHK1 2/4885 |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | POLB 2648/4885SPHK2 2/4885SPHK1 1/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | POLB 3721/4885SPHK2 2/4885SPHK1 1/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | POLB 2648/4885SPHK2 2/4885SPHK1 1/4885 |
| US-11633385-B2 | Combination compositions for treatment of cancer | KRAS, TPMT, CYP2D6 | POLB 697/4885SPHK2 2517/4885SPHK1 1271/4885 |
| US-12370206-B2 | Therapy for inhibition of single-stranded RNA virus replication | EIF2AK2, RNMT, FBL | POLB 71/4885SPHK2 1080/4885SPHK1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.